Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD

[1]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[2]  D. Mannino,et al.  The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide. , 2017, Chronic obstructive pulmonary diseases.

[3]  A. Anzueto,et al.  LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis , 2017, International journal of chronic obstructive pulmonary disease.

[4]  E. Kerwin,et al.  Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study , 2017, International journal of chronic obstructive pulmonary disease.

[5]  F. Martinez,et al.  Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co‐Suspension Delivery Technology in Patients With COPD , 2017, Chest.

[6]  A. de Laat,et al.  Network meta-analysis. , 2017, Journal of oral rehabilitation.

[7]  E. Kerwin,et al.  FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.

[8]  C. Cates,et al.  Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. , 2015, The Cochrane database of systematic reviews.

[9]  S. Dias,et al.  Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis , 2015, Thorax.

[10]  Dave Singh,et al.  Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. , 2015, Respiratory medicine.

[11]  A. Ismaila,et al.  Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis , 2015, International journal of chronic obstructive pulmonary disease.

[12]  H. Watz,et al.  Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4) , 2015, European Respiratory Journal.

[13]  N. Richard,et al.  Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. , 2014, Respiratory medicine.

[14]  E. Kerwin,et al.  Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. , 2014, The Lancet. Respiratory medicine.

[15]  N. Gross,et al.  Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend. , 2014, American health & drug benefits.

[16]  H. Müllerová,et al.  COPD management costs according to the frequency of COPD exacerbations in UK primary care , 2014, International journal of chronic obstructive pulmonary disease.

[17]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[18]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[19]  P. Jones.  St. George's Respiratory Questionnaire: MCID , 2005, COPD.

[20]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[21]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.